ClinicalTrials.gg
Not yet recruitingNCT07186491Updated Jul 21, 2026

Wearable Ultrasound Patch for Breast Imaging

An interventional study of Wearable Ultrasound Patch in Breast Cancer, Breast Abnormalities and Breast Lesion, sponsored by Massachusetts General Hospital. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Breast Neoplasms by Massachusetts General Hospital — 12 open to participants now, 23 under way, none of them phase 3. Breast Neoplasms · Massachusetts General Hospital.

Planned enrollment
28th of 53
50 · median 51
Started
2026
with 1 other
No phase
33 of 66
8 open now
Primary completion
2026-12
later than 4 of 22 live
Registered
63rd of 66
by date

Among the 66 studies in Breast Neoplasms by Massachusetts General Hospital, this one is the 28th largest by planned enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2026, is one of 33 with no phase, reaches primary completion later than 4 of the 22 other live ones, and was the 63rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 66 studies in Breast Neoplasms by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 85 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Breast Neoplasms by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a wearable ultrasound (US) patch can provide reliable whole-breast imaging and accurately detect breast lesions in patients undergoing breast health evaluation. The main questions it aims to answer are:

  • How well does the US-patch detect breast lesions in breasts of different shapes, sizes, and tissue densities?
  • Are there any side effects or discomfort from using the US-patch?

Researchers will compare results from the wearable US-patch to conventional ultrasound to see if the patch provides specific and sensitive findings.

Participants will:

  • Have breast imaging performed with the wearable US-patch, which is applied directly to the breast and secured with a sports bra.
  • Use a guiding software application that helps correctly position the patch.
  • Complete the imaging session in less than 15 minutes, performed by study personnel.
Read the detailed description

This study is designed to evaluate the performance, safety, and reliability of a newly developed conformable wearable ultrasound (US) patch for whole-breast imaging. The device is a flexible, skin-adherent transducer array that provides real-time, three-dimensional imaging of the breast. The primary goal of the study is to assess the diagnostic accuracy of the US-patch device in detecting breast lesions across a variety of breast shapes, sizes, and tissue densities, using conventional handheld ultrasound as the reference standard (ground truth).

Investigators plan to enroll 50 patients over a 12-month period who are undergoing breast health evaluation and either have had or are scheduled for conventional breast ultrasound within one month. Participants will undergo imaging with the US-patch device, which will be applied directly to the breast and secured with a sports bra to maintain consistent contact. The imaging session will take less than 15 minutes and will be performed by trained study personnel.

The diagnostic performance of the US-patch device will be assessed by calculating sensitivity and specificity for breast lesion detection, using true positive, false positive, true negative, and false negative determinations based on radiologist interpretation. Statistical analyses will be performed on a per-lesion basis. Findings will be compared to conventional ultrasound results to determine the accuracy and reliability of the device.

Safety and tolerability will also be evaluated. All participants will be contacted by telephone one week after the imaging session to assess for any delayed adverse effects. Participants who return for follow-up visits within the one-year study period will undergo repeat US-patch imaging, and any adverse events, discomfort, or skin irritation will be documented.

03

Conditions studied

  • Breast Cancer
  • Breast Abnormalities
  • Breast Lesion
  • Breast Asymmetry

Browse trials for

Keywords

  • Breast Imaging
  • Breast Cancer
  • Wearable Imaging
  • Breast Lesion
  • Ultrasound
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Investigators will exclusively enroll patients who have undergone conventional US imaging for their breasts within the past month or are scheduled to undergo it within the upcoming month.
  • Patients with a history of breast cancer or prior breast surgery can also be enrolled
  • Female gender
  • Ages between 18 and 85 years old
  • Being able to understand, communicate, give valid consent to the study, and be understood by researchers

Exclusion criteria

Exclusion Criteria:

  • Having significant health problems (such as chronic or acute cardiovascular diseases, skin diseases) physical and/or behavioral health disabilities limiting participants' ability to follow directions and complete research related activities.
  • Being pregnant
  • Not having intact, healthy breast skin (having open scars or wounds around the location of the breast)
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Breast Imaging with Wearable Ultrasound Device

    Participants in this arm will undergo breast imaging using the wearable ultrasound (US) patch device. The patch is a flexible, skin-adherent transducer array designed to provide whole-breast 3D ultrasound imaging. It will be applied directly to the breast with coupling gel and secured with a sports bra to maintain contact. Imaging will be completed in less than 15 minutes, and results will be compared with conventional ultrasound, which serves as the reference standard.

    Device: Wearable Ultrasound Patch

Interventions

  • DeviceWearable Ultrasound Patch

    The Wearable Ultrasound Patch is a non-invasive imaging device designed to provide real-time breast imaging (3D) through a flexible, skin-adherent US transducer array. The patch conforms to the natural shape of the breast and allows for continuous and comfortable imaging, reducing patient discomfort and improving diagnostic efficiency. It is intended for use as an adjunct imaging tool for breast health assessment, enabling early detection and follow up of lesions in diverse breast morphologies. Patients will use a newly developed software application named "myFUS" to properly position the US probe on their body. The software application will prompt patients through all the required steps to complete the screening. The first imaging session will be performed by the study personnel with the help of the myFUS application.

06

What researchers measure

Primary outcomes

  1. Sensitivity and Specificity of the Wearable Ultrasound Patch for Detecting Breast Lesions

    The primary outcome will assess the diagnostic accuracy of the conformable US-patch device by comparing its breast lesion detection results to conventional handheld ultrasound (reference standard). Sensitivity and specificity will be calculated per lesion using true positive, false positive, true negative, and false negative determinations based on radiologist interpretation. This metric will serve as the main assessment of the device's performance in detecting breast anomalies across a range of breast shapes, sizes, and tissue densities.

    Time frame: From enrollment to 1 week after initial imaging

Secondary outcomes

  1. Safety of the Wearable Ultrasound Patch

    The number of participants experiencing adverse effects, discomfort, or skin irritation related to the wearable US-patch device will be recorded. Participants will be contacted by telephone one week after the initial imaging session, and any follow-up imaging visits within the one year study period will also include assessment of safety and tolerability.

    Time frame: From enrollment to 1 week after the initial US-patch imaging, and at any follow-up visit within the 12-month study period.

07

Study locations

1 site
08

References and documents

Publications

  • Zhou S, Park G, Longardner K, Lin M, Qi B, Yang X, Gao X, Huang H, Chen X, Bian Y, Hu H, Wu RS, Yue W, Li M, Lu C, Wang R, Qin S, Tasali E, Karrison T, Thomas I, Smarr B, Kistler EB, Khiami BA, Litvan I, Xu S. Clinical validation of a wearable ultrasound sensor of blood pressure. Nat Biomed Eng. 2025 Jun;9(6):865-881. doi: 10.1038/s41551-024-01279-3. Epub 2024 Nov 20. PubMed 39567702 ↗
  • Du W, Zhang L, Suh E, Lin D, Marcus C, Ozkan L, Ahuja A, Fernandez S, Shuvo II, Sadat D, Liu W, Li F, Chandrakasan AP, Ozmen T, Dagdeviren C. Conformable ultrasound breast patch for deep tissue scanning and imaging. Sci Adv. 2023 Jul 28;9(30):eadh5325. doi: 10.1126/sciadv.adh5325. Epub 2023 Jul 28. PubMed 37506210 ↗

Individual participant data

Plan to share: Yes — De-identified participant data will be shared with other researchers for scientific and educational purposes. This may include imaging data from the wearable US-patch device, conventional ultrasound results, and associated clinical and demographic information. No personal identifiers (such as names, contact information, or dates of birth) will be included. Data will be shared under a formal data use agreement to ensure confidentiality and proper use.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The results should be made public within 24 months of reaching the end of the study. The study's end is the time point at which the last data items are to be reported, or after the outcome data are mature for analysis.

Access criteria: Only members of the MIT-MGB research team will have access to the IPD.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 3 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Sep 22, 2025
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07186491
Collaborators
Massachusetts Institute of Technology
Responsible party
Tolga Ozmen, MD (Breast Surgery, Surgical Oncology, Massachusetts General Hospital) — Principal investigator
First posted
Sep 22, 2025
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Tolga Ozmen, M.D.
Contact
tozmen@mgh.harvard.edu
617-643-4398
Tolga Ozmen, M.D.
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion